Postmenopausal vaginal atrophy (PVA) refers to reduction in estrogen production after menopause and this condition is also called as vaginal atrophy. Less estrogen leads to thinning, drying, and decreased elasticity of vaginal tissues. Various other factors that lead to decrease in estrogen levels include perimenopause during breast feeding, surgical menopause, pelvic radiation therapy, and chemotherapy.
Market Analysis and Insights: Global Postmenopausal Vaginal Atrophy Drugs Market
Prior to COVID-19, the market for Postmenopausal Vaginal Atrophy Drugs was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of XX% during 2021–2026, whereas post-COVID-19 scenario, the market for Postmenopausal Vaginal Atrophy Drugs is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026. The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Postmenopausal Vaginal Atrophy Drugs market.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Postmenopausal Vaginal Atrophy Drugs market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Postmenopausal Vaginal Atrophy Drugs industry.
Global Postmenopausal Vaginal Atrophy Drugs Scope and Segment
Postmenopausal Vaginal Atrophy Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Postmenopausal Vaginal Atrophy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2015-2026.
The following manufacturers are covered in this report:
Actavis plc
Bionovo, Inc.
Endoceutics, Inc.
Novo Nordisk A/S
Pfizer Inc.
Teva Pharmaceuticals Ltd.
Therapeutics MD, Inc.
Shionogi & Company
Allergan plc
Shionogi & Co. Ltd.
Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Type
Premarin
Vagifem
Estrace
Estring
Femring
Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Application
Vaginal Gels
Creams
Tablets
Rings
Patches
Regional and Country-level Analysis
The Postmenopausal Vaginal Atrophy Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Postmenopausal Vaginal Atrophy Drugs market report are North America, Europe, China and Japan. It also covers key regions (countries), viz, the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of production capacity, price and revenue for the period 2015-2026.
Competitive Landscape and Postmenopausal Vaginal Atrophy Drugs Market Share Analysis
Market Analysis and Insights: Global Postmenopausal Vaginal Atrophy Drugs Market
Prior to COVID-19, the market for Postmenopausal Vaginal Atrophy Drugs was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of XX% during 2021–2026, whereas post-COVID-19 scenario, the market for Postmenopausal Vaginal Atrophy Drugs is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026. The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Postmenopausal Vaginal Atrophy Drugs market.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Postmenopausal Vaginal Atrophy Drugs market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Postmenopausal Vaginal Atrophy Drugs industry.
Global Postmenopausal Vaginal Atrophy Drugs Scope and Segment
Postmenopausal Vaginal Atrophy Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Postmenopausal Vaginal Atrophy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2015-2026.
The following manufacturers are covered in this report:
Actavis plc
Bionovo, Inc.
Endoceutics, Inc.
Novo Nordisk A/S
Pfizer Inc.
Teva Pharmaceuticals Ltd.
Therapeutics MD, Inc.
Shionogi & Company
Allergan plc
Shionogi & Co. Ltd.
Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Type
Premarin
Vagifem
Estrace
Estring
Femring
Postmenopausal Vaginal Atrophy Drugs Breakdown Data by Application
Vaginal Gels
Creams
Tablets
Rings
Patches
Regional and Country-level Analysis
The Postmenopausal Vaginal Atrophy Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Postmenopausal Vaginal Atrophy Drugs market report are North America, Europe, China and Japan. It also covers key regions (countries), viz, the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of production capacity, price and revenue for the period 2015-2026.
Competitive Landscape and Postmenopausal Vaginal Atrophy Drugs Market Share Analysis
1 Study Coverage
1.1 Postmenopausal Vaginal Atrophy Drugs Product Introduction
1.2 Market Segments
1.3 Key Postmenopausal Vaginal Atrophy Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Type
1.4.2 Premarin
1.4.3 Vagifem
1.4.4 Estrace
1.4.5 Estring
1.4.6 Femring
1.5 Market by Application
1.5.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Application
1.5.2 Vaginal Gels
1.5.3 Creams
1.5.4 Tablets
1.5.5 Rings
1.5.6 Patches
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size, Estimates and Forecasts
2.1.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue 2015-2026
2.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales 2015-2026
2.2 Global Postmenopausal Vaginal Atrophy Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Postmenopausal Vaginal Atrophy Drugs Competitor Landscape by Players
3.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers
3.1.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers (2015-2020)
3.1.2 Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers
3.2.1 Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Postmenopausal Vaginal Atrophy Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Postmenopausal Vaginal Atrophy Drugs Revenue in 2019
3.2.5 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Postmenopausal Vaginal Atrophy Drugs Price by Manufacturers
3.4 Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution, Product Types
3.4.1 Postmenopausal Vaginal Atrophy Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Type (2015-2020)
4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020)
4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2015-2020)
4.1.3 Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Application (2015-2020)
5.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020)
5.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2015-2020)
5.1.3 Postmenopausal Vaginal Atrophy Drugs Price by Application (2015-2020)
5.2 Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Postmenopausal Vaginal Atrophy Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Postmenopausal Vaginal Atrophy Drugs by Country
6.1.1 North America Postmenopausal Vaginal Atrophy Drugs Sales by Country
6.1.2 North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
6.3 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Postmenopausal Vaginal Atrophy Drugs by Country
7.1.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country
7.1.2 Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
7.3 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs by Region
8.1.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region
8.1.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
8.3 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Postmenopausal Vaginal Atrophy Drugs by Country
9.1.1 Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country
9.1.2 Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
9.3 Central & South America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs by Country
10.1.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country
10.1.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Actavis plc
11.1.1 Actavis plc Corporation Information
11.1.2 Actavis plc Description and Business Overview
11.1.3 Actavis plc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
11.1.5 Actavis plc Related Developments
11.2 Bionovo, Inc.
11.2.1 Bionovo, Inc. Corporation Information
11.2.2 Bionovo, Inc. Description and Business Overview
11.2.3 Bionovo, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.2.5 Bionovo, Inc. Related Developments
11.3 Endoceutics, Inc.
11.3.1 Endoceutics, Inc. Corporation Information
11.3.2 Endoceutics, Inc. Description and Business Overview
11.3.3 Endoceutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.3.5 Endoceutics, Inc. Related Developments
11.4 Novo Nordisk A/S
11.4.1 Novo Nordisk A/S Corporation Information
11.4.2 Novo Nordisk A/S Description and Business Overview
11.4.3 Novo Nordisk A/S Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Products Offered
11.4.5 Novo Nordisk A/S Related Developments
11.5 Pfizer Inc.
11.5.1 Pfizer Inc. Corporation Information
11.5.2 Pfizer Inc. Description and Business Overview
11.5.3 Pfizer Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.5.5 Pfizer Inc. Related Developments
11.6 Teva Pharmaceuticals Ltd.
11.6.1 Teva Pharmaceuticals Ltd. Corporation Information
11.6.2 Teva Pharmaceuticals Ltd. Description and Business Overview
11.6.3 Teva Pharmaceuticals Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.6.5 Teva Pharmaceuticals Ltd. Related Developments
11.7 Therapeutics MD, Inc.
11.7.1 Therapeutics MD, Inc. Corporation Information
11.7.2 Therapeutics MD, Inc. Description and Business Overview
11.7.3 Therapeutics MD, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.7.5 Therapeutics MD, Inc. Related Developments
11.8 Shionogi & Company
11.8.1 Shionogi & Company Corporation Information
11.8.2 Shionogi & Company Description and Business Overview
11.8.3 Shionogi & Company Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Products Offered
11.8.5 Shionogi & Company Related Developments
11.9 Allergan plc
11.9.1 Allergan plc Corporation Information
11.9.2 Allergan plc Description and Business Overview
11.9.3 Allergan plc Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Allergan plc Postmenopausal Vaginal Atrophy Drugs Products Offered
11.9.5 Allergan plc Related Developments
11.10 Shionogi & Co. Ltd.
11.10.1 Shionogi & Co. Ltd. Corporation Information
11.10.2 Shionogi & Co. Ltd. Description and Business Overview
11.10.3 Shionogi & Co. Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.10.5 Shionogi & Co. Ltd. Related Developments
11.1 Actavis plc
11.1.1 Actavis plc Corporation Information
11.1.2 Actavis plc Description and Business Overview
11.1.3 Actavis plc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
11.1.5 Actavis plc Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Postmenopausal Vaginal Atrophy Drugs Market Estimates and Projections by Region
12.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.2.2 North America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Postmenopausal Vaginal Atrophy Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Postmenopausal Vaginal Atrophy Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
1.1 Postmenopausal Vaginal Atrophy Drugs Product Introduction
1.2 Market Segments
1.3 Key Postmenopausal Vaginal Atrophy Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Type
1.4.2 Premarin
1.4.3 Vagifem
1.4.4 Estrace
1.4.5 Estring
1.4.6 Femring
1.5 Market by Application
1.5.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Application
1.5.2 Vaginal Gels
1.5.3 Creams
1.5.4 Tablets
1.5.5 Rings
1.5.6 Patches
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size, Estimates and Forecasts
2.1.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue 2015-2026
2.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales 2015-2026
2.2 Global Postmenopausal Vaginal Atrophy Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Postmenopausal Vaginal Atrophy Drugs Competitor Landscape by Players
3.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers
3.1.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers (2015-2020)
3.1.2 Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers
3.2.1 Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Postmenopausal Vaginal Atrophy Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Postmenopausal Vaginal Atrophy Drugs Revenue in 2019
3.2.5 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Postmenopausal Vaginal Atrophy Drugs Price by Manufacturers
3.4 Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution, Product Types
3.4.1 Postmenopausal Vaginal Atrophy Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Type (2015-2020)
4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020)
4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2015-2020)
4.1.3 Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Application (2015-2020)
5.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020)
5.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2015-2020)
5.1.3 Postmenopausal Vaginal Atrophy Drugs Price by Application (2015-2020)
5.2 Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Postmenopausal Vaginal Atrophy Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Postmenopausal Vaginal Atrophy Drugs by Country
6.1.1 North America Postmenopausal Vaginal Atrophy Drugs Sales by Country
6.1.2 North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
6.3 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Postmenopausal Vaginal Atrophy Drugs by Country
7.1.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country
7.1.2 Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
7.3 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs by Region
8.1.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region
8.1.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
8.3 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Postmenopausal Vaginal Atrophy Drugs by Country
9.1.1 Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country
9.1.2 Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
9.3 Central & South America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs by Country
10.1.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country
10.1.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Actavis plc
11.1.1 Actavis plc Corporation Information
11.1.2 Actavis plc Description and Business Overview
11.1.3 Actavis plc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
11.1.5 Actavis plc Related Developments
11.2 Bionovo, Inc.
11.2.1 Bionovo, Inc. Corporation Information
11.2.2 Bionovo, Inc. Description and Business Overview
11.2.3 Bionovo, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.2.5 Bionovo, Inc. Related Developments
11.3 Endoceutics, Inc.
11.3.1 Endoceutics, Inc. Corporation Information
11.3.2 Endoceutics, Inc. Description and Business Overview
11.3.3 Endoceutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.3.5 Endoceutics, Inc. Related Developments
11.4 Novo Nordisk A/S
11.4.1 Novo Nordisk A/S Corporation Information
11.4.2 Novo Nordisk A/S Description and Business Overview
11.4.3 Novo Nordisk A/S Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Products Offered
11.4.5 Novo Nordisk A/S Related Developments
11.5 Pfizer Inc.
11.5.1 Pfizer Inc. Corporation Information
11.5.2 Pfizer Inc. Description and Business Overview
11.5.3 Pfizer Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.5.5 Pfizer Inc. Related Developments
11.6 Teva Pharmaceuticals Ltd.
11.6.1 Teva Pharmaceuticals Ltd. Corporation Information
11.6.2 Teva Pharmaceuticals Ltd. Description and Business Overview
11.6.3 Teva Pharmaceuticals Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.6.5 Teva Pharmaceuticals Ltd. Related Developments
11.7 Therapeutics MD, Inc.
11.7.1 Therapeutics MD, Inc. Corporation Information
11.7.2 Therapeutics MD, Inc. Description and Business Overview
11.7.3 Therapeutics MD, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.7.5 Therapeutics MD, Inc. Related Developments
11.8 Shionogi & Company
11.8.1 Shionogi & Company Corporation Information
11.8.2 Shionogi & Company Description and Business Overview
11.8.3 Shionogi & Company Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Products Offered
11.8.5 Shionogi & Company Related Developments
11.9 Allergan plc
11.9.1 Allergan plc Corporation Information
11.9.2 Allergan plc Description and Business Overview
11.9.3 Allergan plc Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Allergan plc Postmenopausal Vaginal Atrophy Drugs Products Offered
11.9.5 Allergan plc Related Developments
11.10 Shionogi & Co. Ltd.
11.10.1 Shionogi & Co. Ltd. Corporation Information
11.10.2 Shionogi & Co. Ltd. Description and Business Overview
11.10.3 Shionogi & Co. Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.10.5 Shionogi & Co. Ltd. Related Developments
11.1 Actavis plc
11.1.1 Actavis plc Corporation Information
11.1.2 Actavis plc Description and Business Overview
11.1.3 Actavis plc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
11.1.5 Actavis plc Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Postmenopausal Vaginal Atrophy Drugs Market Estimates and Projections by Region
12.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.2.2 North America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Postmenopausal Vaginal Atrophy Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Postmenopausal Vaginal Atrophy Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
